Biotechnology • Pharmaceuticals • Alternative Energy • Chemicals/Specialty Materials
Kristina Burow is a Managing Director with ARCH, joining the firm in 2002. Her investment focus includes biotechnology, pharmaceuticals, chemicals and alternative energy companies. Ms. Burow has played a significant role in the formation and financing of Receptos (RCPT, acquired by Celgene - CELG), Sapphire Energy, Lycera, Metacrine, and others.
Ms. Burow is a co-founder of Sapphire Energy and a director of Receptos, Lycera, Trelys, BlackThorn Therapeutics, Metacrine, Unity Biotechnology, AgBiome, and Scholar Rock. She has participated in the funding and development of several other portfolio companies including Siluria Technologies, Ensemble Therapeutics, Kythera Biopharmaceuticals (KYTH), Ikaria, Achaogen (AKAO), Quanterix, Sorbent Therapeutics and Accelerator Corporation.
Prior to ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin outs from GNF.
Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.